This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pick These 5 Bargain Stocks With Amazingly Low EV/EBITDA Ratios
by Anindya Barman
We have screened bargain stocks UNM, SNY, KBH, PVH and VIV based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
3 Reasons Growth Investors Will Love Sanofi (SNY)
by Zacks Equity Research
Sanofi (SNY) possesses solid growth attributes, which could help it handily outperform the market.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Is Innoviva (INVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter
4 Low Price-to-Sales Stocks to Get the Best of the Market
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, MFIN, PAA and KBH hold promise.
AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $54.18, marking a -0.44% move from the previous day.
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
by Zacks Equity Research
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
by Zacks Equity Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
by Kinjel Shah
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
by Sanghamitra Saha
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?
by Zacks Equity Research
Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.
Regeneron (REGN) Gets Label Extension for Cholesterol Drug
by Zacks Equity Research
Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.
Here's Why You Should Add Novo (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed the most recent trading day at $48.56, moving +1.17% from the previous trading session.
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
by Zacks Equity Research
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
ACER's Stock Down on Failure of Phase II Study, Cash Updates
by Zacks Equity Research
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?
by Zacks Equity Research
Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
by Zacks Equity Research
Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.
Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates
by Kinjel Shah
Pfizer (PFE) is set to buy Seagen (SGEN) for $43 billion while Sanofi (SNY) is acquiring Provention Bio. Novo Nordisk (NVO) and Sanofi are looking to cut insulin prices.
Sanofi (SNY) Stock Moves -0.61%: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed the most recent trading day at $47.57, moving -0.61% from the previous trading session.